Mereo BioPharma Group - ADR Financials

$0.34

$0.00 (1.21%)

As on 25-Sep-2026 13:31EDT

Market cap

$48 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

1.6

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	--	0.50	--	10.00	1.51	49.21
Cost of Revenue	0.90	0.13	1.09	2.57	-1.15	24.17
Gross Profit	-0.90	0.37	-1.09	7.43	1.15	25.04
Operating Expenses	33.28	38.62	47.36	35.84	55.57	53.30
Operating Profit (EBIT)	-34.17	-38.26	-47.36	-28.42	-54.43	-28.26
Other Income	--	--	--	--	--	--
Profit before Tax	-28.64	-41.88	-43.25	-30.00	-42.94	19.22
Provision for Tax	-0.57	-1.85	0.02	-0.53	-0.72	2.05
Profit after Tax (Net Income)	-28.08	-41.88	-43.25	-29.47	-42.22	17.17
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-34.20	12.73

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	28.65	40.92	60.97	50.54	51.40	119.01
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	0.39	0.70	1.57	6.48	1.64	34.99
Current Liabilities	5.68	4.30	13.85	9.49	24.38	16.96
Total Liabilities	40.39	45.92	76.39	66.50	77.41	170.96

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	1.31	0.90	1.63	2.74	2.22	36.64
Current Assets	33.40	45.02	74.76	63.76	75.20	134.32
Total Assets	40.39	45.92	76.39	66.50	77.41	170.96
Total Debt*	1.03	0.20	6.43	5.95	15.37	22.66
Net Current Assets	27.72	40.72	60.92	54.27	37.45	86.78

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-30.97	-32.83	-21.13	-48.82	-7.07
Cash Flow from Investing Activities	--	-0.02	-0.70	-0.42	1.99	-0.57
Cash from Financing Activities	--	0.33	46.15	7.97	0.20	104.80
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-0.36	-1.32	-1.39	-0.21	-0.34	0.15
Cash EPS ($)	--	-1.28	-1.36	-0.21	-0.33	0.15
Adjusted Book Value ($)	--	1.29	1.96	0.37	0.41	1.02
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.97	-1.06	-0.15	-0.39	-0.06
Free Cash Flow per Share ($)	--	-0.97	-1.08	-0.16	-0.39	-0.07

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-77.18	-69.83	-47.81	-40.51	23.57
ROE (%)	-80.72	-82.21	-77.58	-57.81	-49.55	34.86
ROA (%)	-50.78	-68.48	-60.54	-40.95	-34.00	13.36
EBIT Margin (%)	--	-8,324.60	--	-271.17	-2,572.20	50.03
Net Margin (%)	--	-8,375.60	--	-294.66	-2,801.59	34.90
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	--	-1.00	5.64	-0.97	124.22
EBIT Growth (%)	52.70	0.62	-54.45	30.04	-257.44	111.98
Net Profit Growth (%)	43.26	3.18	-46.79	30.21	-345.83	108.18
EPS Growth (%)	70.35	0.06	-5.55	0.37	-3.30	1.05
Book Value Growth (%)	-47.39	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-0.32	-2.51	-10.85	-2.21	10.88
Price / Book Value	1.62	0.32	1.78	6.32	1.82	1.57
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-1.21	0.68	-1.11	-10.29	0.28	3.21
Close Price ($)	0.32	0.42	3.50	2.31	0.75	1.60
High Price ($)	3.05	3.84	5.02	2.45	1.85	4.71
Low Price ($)	0.20	0.20	2.23	0.59	0.30	1.45
Market Cap ($ Cr)	48.39	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	0.00	0.11	0.12	0.30	0.19
Short term debt to equity ratio	0.04	0.00	0.10	0.01	0.27	0.01
Current Ratio	5.88	10.46	5.40	6.72	3.09	7.92
Quick Ratio	5.88	--	--	6.59	3.19	8.03
Interest Coverage	-329.01	-163.23	-30.56	-9.41	-9.28	4.71

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	396.60	--	37.32	213.28	2.88
Asset Turnover	--	0.01	--	0.14	0.01	0.38
Receivable days	--	1,911.35	--	126.85	561.47	9.04
Inventory Days	--	--	418.45	-101.10	715.84	-48.80
Payable days	--	5,180.78	803.01	414.21	-1,048.91	56.05
Cash Conversion Cycle	--	--	--	-388.45	2,326.21	-95.81

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.